Total Payments
$338,552
2024 Payments
$324.82
Companies
57
Transactions
566
Medicare Patients
2,960
Medicare Billing
$321,970
Payment Breakdown by Category
Other$281,965 (83.3%)
Travel$25,186 (7.4%)
Consulting$20,360 (6.0%)
Food & Beverage$10,803 (3.2%)
Education$237.68 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $281,965 | 97 | 83.3% |
| Travel and Lodging | $25,186 | 116 | 7.4% |
| Consulting Fee | $20,360 | 16 | 6.0% |
| Food and Beverage | $10,803 | 333 | 3.2% |
| Education | $237.68 | 4 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $229,991 | 220 | $0 (2024) |
| Genentech USA, Inc. | $58,523 | 94 | $0 (2024) |
| Janssen Biotech, Inc. | $19,184 | 23 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $12,094 | 26 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $11,519 | 6 | $0 (2020) |
| Celgene Corporation | $1,967 | 12 | $0 (2022) |
| IntrinsiQ Specialty Solutions, Inc. | $1,500 | 2 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $445.38 | 26 | $0 (2020) |
| Merck Sharp & Dohme LLC | $378.72 | 25 | $0 (2022) |
| Lilly USA, LLC | $300.14 | 9 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $324.82 | 13 | Genentech USA, Inc. ($50.46) |
| 2023 | $109.98 | 5 | Genentech USA, Inc. ($48.07) |
| 2022 | $2,532 | 13 | Celgene Corporation ($1,800) |
| 2021 | $1,617 | 8 | IntrinsiQ Specialty Solutions, Inc. ($1,500) |
| 2020 | $4,853 | 19 | Janssen Scientific Affairs, LLC ($4,040) |
| 2019 | $111,428 | 159 | Incyte Corporation ($57,931) |
| 2018 | $90,987 | 134 | Incyte Corporation ($67,480) |
| 2017 | $126,700 | 215 | Incyte Corporation ($104,535) |
All Payment Transactions
566 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $26.62 | General |
| Category: BioOncology | ||||||
| 11/27/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: Oncology | ||||||
| 09/10/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.32 | General |
| 08/28/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $31.97 | General |
| Category: ONCOLOGY | ||||||
| 07/29/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $34.24 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/20/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $29.48 | General |
| Category: ONCOLOGY | ||||||
| 05/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.54 | General |
| Category: Oncology | ||||||
| 04/19/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: ONCOLOGY | ||||||
| 03/04/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $32.97 | General |
| Category: DESMOID TUMORS | ||||||
| 02/16/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: BioOncology | ||||||
| 02/08/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Oncology | ||||||
| 01/30/2024 | Incyte Corporation | MONJUVI (Drug) | Food and Beverage | Cash or cash equivalent | $26.95 | General |
| Category: Oncology | ||||||
| 01/22/2024 | GENZYME CORPORATION | ENJAYMO (Biological), CABLIVI | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Hematology | ||||||
| 12/14/2023 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: BioOncology | ||||||
| 05/01/2023 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $16.82 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 02/20/2023 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $24.08 | General |
| Category: Oncology | ||||||
| 02/01/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $21.01 | General |
| Category: ONCOLOGY | ||||||
| 01/23/2023 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: BioOncology | ||||||
| 12/19/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA, WELIREG | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2022 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: Oncology | ||||||
| 06/28/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 06/28/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 06/28/2022 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 06/15/2022 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 93 | 96 | $27,988 | $9,616 |
| 2022 | 4 | 126 | 128 | $35,181 | $12,665 |
| 2021 | 19 | 681 | 1,181 | $253,822 | $106,633 |
| 2020 | 39 | 2,060 | 7,601 | $637,257 | $193,055 |
Total Patients
2,960
Total Services
9,006
Medicare Billing
$321,970
Procedure Codes
65
All Medicare Procedures & Services
65 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 39 | 39 | $12,761 | $4,250 | 33.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 22 | $9,458 | $3,054 | 32.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 35 | $5,769 | $2,312 | 40.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 50 | 51 | $16,728 | $5,796 | 34.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 26 | 26 | $11,154 | $4,313 | 38.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 32 | 33 | $5,445 | $1,966 | 36.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 18 | 18 | $1,854 | $590.36 | 31.8% |
| Q5111 | Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg | Office | 2021 | 12 | 300 | $129,618 | $60,335 | 46.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 32 | 120 | $19,200 | $19,200 | 100.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 53 | 53 | $17,384 | $6,144 | 35.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 84 | 93 | $26,970 | $5,459 | 20.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 51 | 65 | $10,725 | $3,965 | 37.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 21 | 21 | $9,009 | $3,407 | 37.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 13 | 16 | $5,360 | $1,780 | 33.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 42 | 42 | $7,980 | $1,270 | 15.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 95 | 115 | $7,475 | $1,172 | 15.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 118 | 148 | $8,140 | $1,119 | 13.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 26 | 27 | $2,781 | $877.17 | 31.5% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 21 | 37 | $2,516 | $445.11 | 17.7% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2021 | 15 | 37 | $1,480 | $344.10 | 23.3% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2021 | 13 | 16 | $1,552 | $294.24 | 19.0% |
| 0001A | Adm sarscov2 30mcg/0.3ml 1st | Office | 2021 | 14 | 14 | $474.32 | $251.72 | 53.1% |
| 83550 | Iron binding capacity | Office | 2021 | 22 | 24 | $840.00 | $209.76 | 25.0% |
| 82728 | Ferritin (blood protein) level | Office | 2021 | 13 | 15 | $1,118 | $204.45 | 18.3% |
| 83540 | Iron level | Office | 2021 | 22 | 24 | $1,200 | $155.28 | 12.9% |
About Dr. Gary Grad, M.D
Dr. Gary Grad, M.D is a Hematology & Oncology healthcare provider based in Elk Grove Village, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629039227.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Grad, M.D has received a total of $338,552 in payments from pharmaceutical and medical device companies, with $324.82 received in 2024. These payments were reported across 566 transactions from 57 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($281,965).
As a Medicare-enrolled provider, Grad has provided services to 2,960 Medicare beneficiaries, totaling 9,006 services with total Medicare billing of $321,970. Data is available for 4 years (2020–2023), covering 65 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Elk Grove Village, IL
- Active Since 03/31/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1629039227
Products in Payments
- JAKAFI (Drug) $200,716
- TECENTRIQ (Biological) $44,991
- DARZALEX (Biological) $26,514
- OPDIVO (Biological) $10,962
- Alecensa (Biological) $8,384
- Avastin (Biological) $4,535
- ERLEADA (Drug) $4,040
- Tarceva (Drug) $400.00
- KEYTRUDA (Biological) $319.42
- KISQALI (Drug) $238.96
- Cabometyx (Drug) $215.86
- Imbruvica (Drug) $188.19
- IMBRUVICA (Drug) $150.15
- CYRAMZA (Drug) $132.77
- Revlimid (Drug) $116.00
- Venclexta (Drug) $110.38
- Neulasta (Biological) $106.57
- VERZENIO (Drug) $100.14
- ZALTRAP (Drug) $99.95
- SUSTOL (Drug) $96.20
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Elk Grove Village
Dr. Gary Kay, M.d, M.D
Hematology & Oncology — Payments: $516,983
Hematology & Oncology $516,983
Dr. Alkarim Tajuddin, M.d, M.D
Hematology & Oncology — Payments: $44,272
Hematology & Oncology $44,272
Dr. Bruce Bank, M.d, M.D
Hematology & Oncology — Payments: $34,272
Hematology & Oncology $34,272
Dr. Ronald Shade, M.d, M.D
Hematology & Oncology — Payments: $32,380
Hematology & Oncology $32,380
Dr. Steven Kanter, M.d, M.D
Hematology & Oncology — Payments: $24,270
Hematology & Oncology $24,270
Dr. Gary Gordon, M.d, M.D
Hematology & Oncology — Payments: $22,948
Hematology & Oncology $22,948